Track market-moving stories before they get noisy

Completion of three additional 25 MW data halls brings fully operational capacity at Polaris Forge 1 to 250 MW  | Source: Applied Digital Corporation

DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a U.S. based designer, developer, owner and operator of large-scale, purpose-built data centers engineered to support high-performance computing (“HPC”) workloads, including artificial intelligence (“AI”), machine learning, and other accelerated-compute applications, today announced it has achieved Ready for Service for the second phase of Building 2 at its Polaris Forge 1 campus, delivering an additional 75 MW of critical IT load across three 25 MW data halls.

The milestone completes Building 2’s full 150 MW of critical IT load and brings fully operational critical IT load at Polaris Forge 1 to 250 MW. The fully leased AI Factory Campus is contracted to deliver 400 MW of critical IT load at full buildout.

“Bringing another 75 MW of AI infrastructure online at Polaris Forge 1 further demonstrates our ability to turn large-scale power into operational AI infrastructure,” said Wes Cummins, Chairman and Chief Executive Officer of Applied Digital. “Securing power is only the starting point. The real work is designing, building, commissioning, and operating the infrastructure that transforms those megawatts into usable capacity for customers. That is the capability we continue to scale across our platform.”

The latest delivery follows the first 100 MW building at Polaris Forge 1 and the initial 75 MW phase of Building 2. With 250 MW now operational, Polaris Forge 1 reflects Applied Digital’s repeatable approach to developing and operating large-scale infrastructure purpose-built for advanced AI and high-performance computing workloads.

Polaris Forge 1 is located in Ellendale, North Dakota, where Applied Digital has operated since 2021 and built long-standing relationships with local leaders, partners, and community stakeholders. As the campus continues to expand, the Company remains focused on responsible development, local partnership, and creating long-term value in the communities where it builds.

About Applied Digital

Applied Digital (Nasdaq: APLD) — named Best Data Center in the Americas 2025 by Datacloud — designs, builds, and operates high-performance, sustainably engineered data centers and colocation services for artificial intelligence, cloud, networking, and blockchain workloads. Headquartered in Dallas, TX, and founded in 2021, the company combines hyperscale expertise, closed-loop cooling, and rapid deployment capabilities to deliver secure, scalable compute at industry-leading speed and efficiency, while creating economic opportunities in underserved communities through its AI Factory franchise model.

Learn more at applieddigital.com or follow @APLDdigital on X and LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and objectives, and future financing plans. These statements use words, and variations of words, such as “will,” “continue,” “build,” “future,” “increase,” “drive,” “believe,” “look,” “ahead,” “confident,” “proven,” “deliver,” “outlook,” “expect,” “project” and “predict.” Other examples of forward-looking statements may include, but are not limited to, (i) statements that reflect perspectives and expectations regarding lease agreements and any current or prospective data center campus development; (ii) statements about the high-performance computing (HPC) industry; (iii) statements of company plans and objectives, including the company’s evolving business model, or estimates or predictions of actions by suppliers; (iv) statements of future economic performance; and (v) statements of assumptions underlying other statements and statements about the company or its business. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the company’s expectations and projections. These risks, uncertainties, and other factors include, among others: whether or not our customers exercise the renewal options under their leases with us (if not, we will not recognize further revenue from such customer under its respective lease); our ability to complete construction of our data center campuses as planned; the lead time of customer acquisition and leasing decisions and related internal approval processes; changes to artificial intelligence and HPC infrastructure needs and their impact on future plans; costs related to the HPC operations and strategy; our ability to timely deliver any services required in connection with completion of installation under lease agreements; our ability to raise additional capital to fund the ongoing datacenter construction and operations; our ability to obtain financing of datacenter leases and more broadly for our development and general corporate activities; our dependence on principal customers, including our ability to execute and perform our obligations under our leases with key customers; our ability to timely and successfully build new hosting facilities with the appropriate contractual margins and efficiencies; power or other supply disruptions and equipment failures; the inability to comply with regulations, developments and changes in regulations; cash flow and access to capital; availability of financing to continue to grow our business; decline in demand for our products and services; maintenance of third party relationships; and conditions in the debt and equity capital markets. A further list and description of these risks, uncertainties, and other factors can be found in the company’s most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, including in the sections captioned “Forward-Looking Statements” and “Risk Factors,” and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, on the company’s website (www.applieddigital.com) under “Investors,” or on request from the company. Information in this press release is as of the dates and time periods indicated herein, and the company does not undertake to update any of the information contained in these materials, except as required by law.

Media Contact
JSA (Jaymie Scotto & Associates)
(856) 264-7827
[email protected]

Investor Relations Contacts
Matt Glover or Ralf Esper
Gateway Group, Inc.
(949) 574-3860
[email protected]

A single capacity announcement from Toshiba sent two of this year's hottest storage stocks into freefall while the rest of the memory sector shrugged it off, and the reason behind that split tells you everything about where the HDD trade…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

One capacity announcement from Toshiba is splitting the storage trade in two, hitting the hard disk drive (HDD) makers heavily while the broader memory group barely moves. Seagate Technology Holdings (NASDAQ:STX | STX Price Prediction) stock is down 10% to $849.79 in morning trading, the sharpest decline among the storage names. Meanwhile, Western Digital (NASDAQ:WDC) shares are slipping 7% to $429.45 as the pure-play HDD company takes a similar hit.

The Roundhill Memory ETF (CBOE:DRAM) is up 0.82% to $62.54, even though Seagate and Western Digital sit among its holdings. Meanwhile, the Invesco QQQ Trust (NASDAQ:QQQ) is up 1.17% to $750.73, so large-cap technology stocks are trading stronger overall. The Roundhill fund would have dropped alongside the two drive makers in a broad memory selloff, so the damage looks confined to one product line.

Demand from artificial intelligence (AI) data centers turned Seagate and Western Digital into two of the year’s standout technology stocks, and Toshiba wants a bigger share of it. Both Seagate and Western Digital beat earnings estimates in every quarter of fiscal 2026, which puts the focus of the selloff directly on future supply.

Toshiba Plans to Double Its Hard Drive Output Toshiba plans to double its HDD production capacity, with the expansion centered on its manufacturing facility in the Philippines. The Japanese company is aiming the added output at storage demand from AI data centers, the same customers that have fueled surging results at Seagate and Western Digital.

Toshiba, the smallest of the three companies that control HDD manufacturing, has set a medium-term target of 30% of the market measured by storage capacity. Reaching that goal would mean taking market share from Seagate and Western Digital in an industry where tight supply has supported rising prices.

Hard Drive Makers Slide While Memory Stocks Hold Firm What Seagate and Western Digital share, and what separates both from the rest of the storage group, is concentrated exposure to the exact product Toshiba plans to build more of. Micron Technology (NASDAQ:MU), SanDisk (NASDAQ:SNDK) and SK Hynix (NASDAQ:SKHY) benefit from the same AI infrastructure boom through memory chips and flash storage without that HDD concentration. That likely explains why the Roundhill fund is holding steady.

Both stocks’ big runs this year leave them sensitive to news suggesting the industry’s supply and demand balance could loosen. Before the drop, Seagate shares were up 210% year to date (YTD), and Western Digital stock was up 150% YTD.

Western Digital CEO Irving Tan linked pricing directly to scarcity on the company’s August 5 earnings call, stating, “In the very tight supply environment that we’re in, that provides us an opportunity for increased pricing leverage as well.” Seagate has leaned on the same discipline, with chief executive Dave Mosley asserting on the company’s April 28 call, “The total number of units is not really increasing.” Toshiba’s plan to double its output works directly against that approach.

What to Watch Next Long-term contracts give Seagate and Western Digital some protection against Toshiba’s added supply. Nearline capacity at Seagate (the high-capacity drives sold to data centers) was almost fully allocated through calendar 2027, the company stated in April. Guidance from Western Digital calls for the company’s fiscal Q1 2027 revenue to reach $4.1 billion, plus or minus $100 million.

What remains unknown is how quickly Toshiba’s new capacity reaches cloud buyers. Any slide in the Roundhill Memory ETF to match the two stocks would suggest the worry is spreading beyond HDDs.

Contact [email protected] for any questions or corrections.

Coca-Cola just cut another quarterly check to shareholders, but the real story is what the payout reveals about the company's financial strength, its ongoing IRS battle, and whether 64 consecutive years of dividend raises are in jeopardy.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Coca-Cola (NYSE:KO | KO Price Prediction) shareholders received $0.53 per share on October 1, 2026. The board declared the dividend on July 15, 2026, and the ex-dividend date was September 15, 2026. Shares held before that date earned the dividend. Buyers from that date forward must wait for the next quarter.

The payout for this quarter is the same as the prior quarter’s. The annual raise came earlier in the year, so this check adds one more quarter to one of the longest dividend records on the market.

Dividend Scorecard: Payment, Pace, and Price Metric Figure Quarterly dividend paid October 1, 2026 $0.53 Same-quarter payment a year earlier (October 1, 2025) $0.51 Trailing 12-month dividends per share $2.10 Annualized forward dividend rate $2.12 Share price (close, October 1, 2026) $86.10 Trailing dividend yield 2.5% The forward rate of $2.12 runs ahead of the trailing total of $2.10, because the higher quarterly rate has not yet been in place for a full four quarters.

The yield is moderate. The stock has gained 24.6% year to date and 30.3% over the past year, and that rally has pulled the yield lower even as the payout grew. Shares trade at about 26 times trailing earnings and 25 times forward earnings. They trade between a 52-week low of $65.84 and a high of $92.49.

Safety Check: Earnings and Cash Flow Cover the Payout Coverage matters more than yield here, and the coverage numbers hold up. Trailing diluted EPS is $3.33, well above the $2.10 in dividends paid per share over the same stretch. In the quarter ended June 30, 2026, Coca-Cola earned $4.43 billion in net income and paid $2.28 billion in common dividends.

Furthermore, operating cash flow reached $5.52 billion in the second quarter against capital spending of $418 million. Management reported first-half free cash flow of “approximately $6.9 billion,” up from the prior year. Full-year free cash flow guidance is about $12.4 billion, raised from $12.2 billion. For scale, the company paid $8.78 billion in dividends during all of 2025.

There is a caveat. Reported operating cash flow for 2025 was $7.41 billion, below the dividend outlay. The shortfall came from a one-time item: the Fairlife contingent consideration payment made in the first quarter of 2025, which drove operating cash flow in that quarter to negative $5.20 billion. Cash generation in the four quarters since then points to a business that funds its dividend from ongoing operations.

Balance Sheet Leaves Room to Spare As of June 30, 2026, Coca-Cola held $12.91 billion in cash and equivalents against $43.54 billion in total debt. Shareholder equity rose to $36.15 billion at the end of 2025 from $32.17 billion in the prior year. Management put the leverage figure in context during the July earnings call:

Our balance sheet remains strong with our net debt leverage of 1.4 times EBITDA, which is below our target range of 2 to 2.5 times. Given the momentum of our business and the strength of our balance sheet, we have increased flexibility and optionality to continue to both reinvest in our business and return capital to share owners.

63 Straight Years of Raises Behind This Payment Coca-Cola had raised its dividend for 63 consecutive years through 2025. The move from $0.51 to $0.53 per quarter shows the 2026 increase went through on schedule. That record puts Coca-Cola well past the 50-year mark that defines a Dividend King.

Total cash paid to shareholders has risen steadily, from $7.25 billion in 2021 to $7.62 billion in 2022, $7.95 billion in 2023, $8.36 billion in 2024, and $8.78 billion in 2025. Over the same period, the share count edged down from 4.34 billion to 4.31 billion, so each remaining share captures a slightly larger portion of the payout.

Operating Momentum Supports the Next Raise The dividend is backed by a growing business. Second-quarter EPS of $0.97 beat the $0.9323 consensus estimate. Revenue of $13.38 billion rose 6.7% year over year. Operating margin expanded to 34.9% from 34.1%, and global unit case volume grew 5%, with Coca-Cola Zero Sugar up 16%.

The company raised its 2026 outlook and now expects comparable EPS growth of “9 to 10% versus $3 in 2025,” along with organic revenue growth of “approximately 5%.” Chief Executive Henrique Braun said, “I’m confident we are well positioned to deliver on our raised 2026 guidance.” Some institutional investors see value at current levels. A Fidelity fund manager recently told Barron’s that Coca-Cola shares look like bargains.

What Income Holders Should Track Next IRS tax dispute: Coca-Cola presented oral arguments before the 11th Circuit Court of Appeals in June, and management said, “the timing of a decision from the appellate court is unknown at this stage.” A win would give the company access to funds already deposited with the IRS. A loss is laid out in its financial statements. Third-quarter earnings report: Management expects concentrate shipments to lag unit case volume by a point in the third quarter, which could make reported growth look softer than underlying demand. Free cash flow delivery: Hitting the $12.4 billion target would leave dividend coverage comfortable going into the next annual increase decision. Consumer pressure: Management noted that lower-income consumers remain under pressure in North America and globally, a factor that bears on volume. Income investors can take comfort knowing that earnings cover the dividend with room to spare, 2026 free cash flow is on track to exceed the full annual payout, leverage remains below management’s own target, and more than six decades of continuous increases stand behind each quarterly check. Also, the yield is moderate after a strong run in the stock.

Contact [email protected] for any questions or corrections.

Amazon and Alphabet both booked staggering Anthropic gains last quarter, yet the two hyperscalers are playing completely different games with the AI company heading toward a public listing.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

In their second-quarter reports, Amazon (NASDAQ:AMZN | AMZN Price Prediction) and Alphabet (NASDAQ:GOOGL) both booked huge Anthropic gains. Amazon recorded a $53.4 billion non-operating gain, mostly from Anthropic. Alphabet logged $99 billion in unrealized equity gains. Anthropic targets a late-2026 window for its IPO. A listing would benefit each company in different ways.

Trainium Drives AWS While Gemini Drives Google Cloud AWS revenue reached $42.2 billion, up 36.7%, its fastest growth in 18 quarters. CEO Andy Jassy called Anthropic and OpenAI “the two leading AI labs in the world” and said both have made multi-year, multi-gigawatt commitments to Trainium. Project Rainier runs on more than 500,000 Trainium2 chips for training Claude. The commitment ties Anthropic closely to AWS infrastructure.

Google Cloud grew 82% to $24.77 billion. Anthropic runs workloads on Google TPUs, yet Sundar Pichai promoted Gemini, mentioning that nearly 90% of the Fortune 100 use Gemini Enterprise. Google launched Gemini 4 Argon, a model competing directly with Claude.

Anthropic Lens Amazon Alphabet Q2 Equity Gain $53.4B, mostly Anthropic $99.03B, includes Anthropic Compute Tie Trainium, up to 5 GW committed TPU workloads Claude Relationship Hosts Claude Opus 5 on Bedrock Gemini competes head-on Amazon Is Anthropic’s Partner. Alphabet Also Competes With It. Amazon’s chip business has passed a $25 billion run rate and is growing at triple-digit rates. Anthropic is a major proof point for Trainium. Jassy noted there is “a real chance” Amazon will sell Trainium chips outside AWS, and a successful Anthropic IPO would strengthen that sales pitch.

Alphabet’s balance sheet faces pressure. It raised $49.6 billion in equity and suspended buybacks. Long-term debt rose from $46.5 billion to $98.2 billion. A public Anthropic stake would give Alphabet an asset it could eventually sell.

Anthropic’s Public Valuation Could Move Both Earnings Reports A public price will set a new value for both stakes. Watch whether Anthropic shifts more compute toward TPUs as it grows, and monitor cash burn. Amazon’s trailing free cash flow was -$7.6 billion, and Alphabet’s quarterly figure was -$5.86 billion. IPO gains are paper gains. Data centers are paid for in cash, and the power, cooling, and networking suppliers behind that expansion are a trade of their own (we covered seven of them in a free AI infrastructure report).

Amazon Holds the Deeper Anthropic Link Investors Can’t Ignore Amazon benefits twice: through the equity mark and through years of contracted Trainium demand. Jassy said the “lion’s share of capacity in 27” is already reserved, with Anthropic accounting for a large part. Alphabet has the bigger paper gain and stronger stock performance, up 38.47% over the past year versus Amazon’s 12.51%. That makes Alphabet the broader AI story and Amazon the company with more direct Anthropic exposure.

Contact [email protected] for any questions or corrections.

Nike just slipped below its 52-week low while the broader market climbs, but one analyst sees a path to gains that would leave the rest of Wall Street stunned. The question is whether the turnaround math actually works.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Nike (NYSE:NKE | NKE Price Prediction) currently trades at $35.10. The average analyst price target stands at $45.63, which implies 30% upside.

Nike is the world’s largest athletic footwear and apparel supplier, now going through a turnaround under CEO Elliott Hill. Piper Sandler analyst Abbie Zvejnieks rates the stock Overweight. Her $75.00 target implies more than 113% upside, far above Wall Street’s consensus.

The gap between consensus and Piper’s target reflects the core debate: one side views a fallen blue chip near its bottom; the other sees a restructuring requiring more time and cost than bulls expect.

A Shrinking Sales Outlook and a China Reset Sent Nike to a 52-Week Low Nike’s guidance did the most damage. Management expects fiscal 2027 revenue to fall by a high-single-digit percentage, with adjusted EPS of $1.15 to $1.35 versus fiscal 2026 EPS of $2.10. Shares are down 43.44% year to date.

First-quarter revenue fell 4.3% to $11.21 billion, missing the $11.32 billion consensus, though EPS of $0.48 beat the $0.44 estimate. Greater China revenue dropped 22%, Converse fell 28%, and Jordan Brand declined by a mid-teens percentage. Sportswear revenue fell by a low-double-digit percentage after Nike cut Dunk revenue by nearly 50%. Management warned that China “actually gets worse from a revenue perspective for the balance of this year.”

While the sector is weak, Nike is pulling back supply and clearing inventory, making much of this decline company-specific.

Piper Sandler’s $75 Case Rests on Cost Cuts and a Performance Comeback Piper’s bull case rests on three points:

Cost cuts that free up $600 million to $1 billion in yearly savings, adding 130 to 200 basis points to operating margin. A wholesale restructuring that wins back shelf space at retailers. New running and performance shoes that take back share from challenger brands. Jefferies has also stayed bullish, with a target around the $75 level.

Nike’s Pace restructuring targets about $2.5 billion in total savings through fiscal 2031, with most coming in fiscal 2029 and 2030. Performance business grew by a high-single-digit percentage and running by double digits. Hill called that “a proof point” for the strategy. Nike plans to share a long-term financial framework at its November investor day.

The Street remains largely conservative. Of 39 analysts, one rates Nike a Strong Buy, 10 a Buy, 25 a Hold, one a Sell, and two a Strong Sell. Management also said pain will “bleed in a little bit into fiscal 28,” so recovery will take time.

Deckers Outdoor (NYSE:DECK) has the largest consensus upside in the group, which also includes Lululemon Athletica (NASDAQ:LULU).

Nike Slips Below Its 52-Week Low as the S&P 500 Climbs At $35.10, Nike stands just under its $35.16 52-week low and far below its $72.39 high. The $45.63 consensus target from 39 analysts implies 30% upside.

Shares fell 7.92% over the past month and 51.13% over the past year, while the S&P 500 gained 12.04% year to date and 14.3% over the past year. Nike trades at about 21 times forward earnings and pays a $0.410 quarterly dividend that management says it can support “under all scenarios.”

Nike’s Recovery Case Is Credible, but $75 Is Years Away Upside would build if the November investor day lays out a credible path to higher margins, if Pace savings arrive on schedule, and if performance growth offsets cuts in Sportswear and Jordan. The road to $75 runs through wider margins on steady sales.

Risks would mount if China drops beyond fiscal 2027, if Converse keeps shrinking, or if Dunk and Jordan cutbacks leave a gap that performance products can’t fill. Adjusted EPS is guided to $1.15 to $1.35, leaving little room for a guidance cut.

I lean cautiously bullish. The 30% consensus upside looks reachable if Pace delivers. The dividend is backed by $8.4 billion in cash and short-term investments. Piper’s $75 target is the best case, requiring nearly everything to go right.

Contact [email protected] for any questions or corrections.

Altria's 6.6% yield and 60 consecutive raises look bulletproof until you dig into what sits beneath them: a shrinking core business, a failed smoke-free pivot, and a balance sheet with liabilities that dwarf its assets.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Altria (NYSE:MO | MO Price Prediction) has more risk than its yield suggests. The yield is easy to like. A forward dividend of $4.44 a share against a $66.94 stock price works out to about 6.6%, and the board just raised the quarterly payout to $1.11. To a retiree, that looks like a reliable paycheck. Behind it sit a shrinking core business, a smoke-free strategy that keeps losing ground, and a balance sheet with no buffer.

Cigarette Volumes Keep Falling, and Price Hikes Are Covering the Gap Domestic cigarette shipment volume fell 10.0% in 2025. Marlboro’s retail share dropped 1.4 points to 39.7% in Q1 2026, then lost another 1.5 share points year over year in Q2 as discount share grew 2.6 share points. Altria fills the hole with price. Marlboro’s retail price rose about 7% in Q2. That strategy depends on smokers who, by management’s own account, are stretched. Altria’s chief executive told analysts in July, “The consumer remains under pressure.”

Altria Is Losing the One Category That Is Growing Altria took $2.2 billion in NJOY e-vapor impairment charges in 2025, and NJOY ACE has no announced return date. In nicotine pouches, which reached 58.1% of U.S. oral tobacco, on! saw its category share fall 4.2 points to 13.4% in Q1 2026, down from 16.7% in Q2 2025. on! shipments then dropped 4.2% in Q2. Rivals are getting the growth Altria needs.

Dividend Coverage Has Thinned and the Balance Sheet Offers No Buffer Altria paid $7.0 billion in dividends in 2025 against net income of $6.95 billion. Stockholders’ equity stood at negative $3.2 billion in Q1 2026, with total liabilities of $37.7 billion above total assets of $34.6 billion. The forward dividend uses up about 78% to 79% of 2026 adjusted EPS guidance of $5.61 to $5.72, which implies just 3.5% to 5.5% growth, partly helped by buybacks. Even the Q1 revenue jump of 20.1% leaned on 610 million contract-manufactured export sticks.

Bulls point to the record. The 2025 raise was Altria’s 60th increase in 56 years, and debt-to-EBITDA stands at a manageable 1.9 times. That run was built on pricing power over a shrinking unit base, and that power weakens as smokers trade down. A yield this high usually means the market suspects something, and we broke down the seven warning signs that a payout is about to be cut in a free dividend trap guide. Shares are also up 21.73% year to date, so buyers today pay more for the same declining business.

Philip Morris Offers a Better-Built Route to Tobacco Income Among tobacco peers, Philip Morris International (NYSE:PM) has the growth engine Altria lacks. Smoke-free products made up about 42% of its Q2 2026 net revenue, revenue grew 10.37%, and 2026 adjusted EPS guidance calls for 9.5% to 11.5% growth. It also has negative equity of $6.66 billion, so its edge rests entirely on growth. Still, its dividend is backed by an expanding business.

Watch on! pouch share and Marlboro retail share in the next report, because a stop in both declines for several straight quarters would signal the core business is stabilizing.

Contact [email protected] for any questions or corrections.

The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that ecopipam reduces tic severity, provides sustained benefit over time and helps prevent relapse without some of the complications associated with antipsychotic agents.¹Ecopipam is an investigational, selective D1 (dopamine) receptor antagonist targeting dopaminergic signaling in the brain’s direct motor pathway implicated in Tourette syndrome.Unlike D2 antipsychotics that target D2 receptors in the indirect pathway, ecopipam selectively targets D1 receptors in the direct motor pathway, offering a differentiated approach that may reduce tic severity while potentially avoiding common adverse events associated with D2-targeting therapies.1 PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome.1,2 The review evaluates current treatment limitations and details how selectively targeting D1 receptors in the brain’s direct motor pathway may offer a differentiated, non-antipsychotic approach for managing tics in pediatric patients.1

“Tourette syndrome affects up to 1 in 130 children globally and can have a profound impact on a child's daily life, education and social development,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva. “The review published in the Journal of Child Neurology reinforces the potential of ecopipam’s selective dopamine D1 receptor approach. This is the kind of innovative programs we are pursuing at Teva—advancing differentiated science to address meaningful unmet needs.”

The comprehensive review details the neurobiological rationale for D1 receptor antagonism compared with existing therapies. In Tourette syndrome, elevated dopaminergic activity in the basal ganglia is proposed to contribute to the expression of involuntary tics. Because D1 receptors are primarily expressed by neurons in the direct motor pathway, ecopipam is hypothesized to block excess dopaminergic activity in this pathway, thereby normalizing downstream basal ganglia signaling and movement patterns. In contrast, traditional antipsychotics target D2 receptors, which are primarily associated with the indirect pathway.

This mechanistic distinction is supported by clinical data synthesized across the ecopipam development program. In a Phase 3 trial (n=216, including 167 pediatric), continued ecopipam treatment cut the risk of tic relapse by 50% versus placebo in pediatric participants (HR: 0.5; P=0.008), building on Phase 2b and 12-month open-label data showing sustained reductions in tic severity. Across clinical trials, the most common adverse events included somnolence, headache, insomnia, fatigue and anxiety while ecopipam was not associated with clinically relevant weight gain, adverse metabolic effects or drug-induced movement disorders. The potential importance of this efficacy and tolerability profile is underscored by real-world treatment persistence data, which show that treatment discontinuation rates among patients newly treated with D2 receptor antagonists were 61.2% by 3 months and 82.1% by 18 months.1

“Treatment of Tourette syndrome can be complex, as clinicians must balance tic improvement with the side effect profiles of current therapies,” said Donald L. Gilbert, M.D., M.S., senior author of the review and Pediatric Movement Disorders and Tourette Syndrome Specialist, Division of Neurology, Cincinnati Children’s Hospital Medical Center. “Ecopipam selectively targets the dopamine D1 receptor, and the data reviewed in this publication – demonstrating reduced tic severity and sustained benefit without significant weight gain, metabolic complications or movement disorders – supports continued research into D1 receptor antagonism for Tourette syndrome.”

For more information on the review published online in the Journal of Child Neurology, click here.

About Tourette Syndrome 
Tourette syndrome is a chronic neuro-developmental disorder characterized by involuntary motor and vocal tics beginning in childhood, often between 5 and 10 years of age.3 For people living with Tourette syndrome, symptoms can be frequent, visible and disruptive, affecting everyday life.3

About Ecopipam and Its Clinical Program 
Ecopipam is a first-in-class investigational therapy designed to block dopamine signaling at the D1 receptor. D1 receptor hypersensitivity may contribute to repetitive and compulsive behaviors associated with Tourette syndrome. 

Ecopipam was granted Priority Review by the FDA with Orphan Drug designation for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer. 

The D1AMOND Phase 2b Trial was a 12-week randomized, double-blind, placebo-controlled trial that studied 153 pediatric participants across 68 sites in North America and Europe. The primary efficacy endpoint was the change in the YGTSS-TTS, i.e., sum of the motor and vocal tic scores, from baseline to end of therapy.4 The associated Phase 2b open-label extension enrolled 121 pediatric subjects from the Phase 2b trial and followed them for up to 12 months’ duration to evaluate the long-term safety and tolerability of ecopipam.5 The subsequent D1AMOND Phase 3 Trial was a double-blind, placebo-controlled, randomized withdrawal trial enrolling a total of 216 pediatric and adult participants into an open-label stabilization period and randomizing 104 participants (90 pediatric, 14 adult) across 77 sites in North America and Europe. The objective of this study was to evaluate the maintenance of efficacy of ecopipam in pediatric and adult responders utilizing the YGTSS-TTS change from randomization or increased Tourette-specific care to determine relapse.6 While this Phase 3 trial included adult participants, the accepted NDA and resulting indication sought by Teva are exclusively for pediatric patients. 

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. 

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully develop, obtain regulatory approval for and commercialize ecopipam; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam for the treatment of pediatric patients with Tourette syndrome; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Karkanias, G. B., Flatt, J. A., Korb, R. T., Munschauer, F. E., Wanaski, S. P., Cunniff, T. M., & Gilbert, D. L. (2026). Targeting Dopamine Pathways for the Treatment of Tourette Syndrome. Journal of Child Neurology. https://doi.org/10.1177/08830738261491159U.S. Food and Drug Administration (FDA) Approval Records: Haloperidol (1969), Pimozide (1984), Aripiprazole (2014); Pringsheim, T., et al. (2019). The pharmacological management of tic disorders: an updated practice guideline. Neurology. CDC | Tourette Syndrome | Data and Statistics on Tourette Syndrome, 2024; Mayo Clinic | Tourette Syndrome – Diagnosis and treatment, 2025. Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette Syndrome: A Randomized Trial. Pediatrics. 2023;151(2):e2022059574. doi:10.1542/peds.2022-059574 Gilbert DL, Kim DJB, Miller MM, et al. Safety and Effect of 12-Month Ecopipam Treatment in Pediatric Patients with Tourette Syndrome. Mov Disord Clin Pract. 2025;12(8):1157-1166. doi:10.1002/mdc3.70091. Gilbert DL, Atkinson SD, Kim DJB, et al. Efficacy and Safety of Ecopipam for Tourette Syndrome: A Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026;83(7):645–653. doi:10.1001/jamaneurol.2026.1431 Teva Media Inquiries:
[email protected]

Teva Investor Relations Inquiries:
[email protected]

Key Takeaways Oracle's multicloud database revenues surged 353% as its cloud consumption shift accelerated.Pay-per-use pricing expands Oracle's market, but partner-hosted deployments add capital intensity.MongoDB and Snowflake are expanding margins, while Oracle's infrastructure buildout weighs on free cash flow. Oracle Corporation's (ORCL - Free Report) database business is being repositioned around cloud consumption, raising a central question: can its historically lucrative database franchise sustain margins as delivery shifts from licenses to usage?

Oracle made Exadata Database Service on Exascale Infrastructure generally available on Oracle AI Database@AWS, extending Exadata-class performance with pay-per-use pricing. Oracle also signed an expanded long-term collaboration agreement with Amazon Web Services (“AWS”) to accelerate customer migrations. The service now spans 22 AWS Regions.

The momentum was evident in first-quarter fiscal 2027 results. Multicloud database revenues surged 353% year over year, while multicloud customers rose 180%, and Oracle completed its planned expansion across Azure and AWS, reaching 70 multicloud database regions.

The shift, however, carries margin trade-offs. Software revenues, home to the legacy license and support streams, declined 3% to $5.5 billion as customers kept migrating on-premise workloads to the cloud. Pay-per-use pricing widens the addressable market but lowers entry price points, while partner-hosted deployments rely on Oracle hardware placed inside AWS data centers, adding capital intensity absent from traditional support contracts.

Consolidated profitability has held firm so far. Total revenues rose 30% to $19.3 billion, while non-GAAP operating income climbed 31% to $8.2 billion, implying a margin of about 42%, roughly in line with the year-ago level. GAAP operating income jumped 57% to $6.7 billion. Yet capital expenditures reached $28.5 billion, leaving free cash flow at negative $5 billion. Oracle expects to raise about $40 billion through debt and equity in fiscal 2027.

Guidance points to continued scale. For the second quarter, Oracle projects revenue growth of 30-34%, cloud revenue growth of 65-71% and non-GAAP EPS of $1.85-$1.93. For fiscal 2027, it expects revenues of at least $90 billion and non-GAAP EPS of $8.10, supported by remaining performance obligations of $664 billion.

Whether database margins endure will depend on multicloud volumes outpacing the erosion of legacy software revenues, while infrastructure costs keep climbing.

MDB & SNOW Show Consumption Margins ScalingMongoDB (MDB - Free Report) and Snowflake (SNOW - Free Report) offer a useful benchmark for consumption-based database economics. In second-quarter fiscal 2027, MongoDB’s revenues grew 30% to $771.8 million, with Atlas up about 29%, while its non-GAAP operating margin widened to 24% from 15%. MongoDB expects full-year margin expansion of roughly 250 basis points.

Snowflake’s product revenues increased 37% to $1.49 billion and non-GAAP operating margin improved to 15.3% from 11.1%. Snowflake raised its fiscal 2027 margin outlook to 14.5%. Both remain well below Oracle's roughly 42% non-GAAP operating margin, yet each is expanding profitability without the capital-intensive infrastructure buildout that is now weighing on Oracle's free cash flow.

ORCL’s Price Performance, Valuation & EstimatesORCL shares have plunged 29.2% year to date, underperforming the Zacks Computer and Technology sector’s growth of 22.4% and the Zacks Computer - Software industry’s decline of 3.5%.

ORCL’s YTD Price Performance
Image Source: Zacks Investment Research

ORCL’s valuation remains relatively attractive, with the stock trading at a trailing 12-month P/E ratio of 20.3X, lower than the sector average of 1.02X. Oracle has a Value Score of C.

ORCL’s Valuation Chart
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for ORCL’s fiscal 2027 earnings is currently pegged at $8.12 per share. The estimate implies 6.42% year-over-year earnings growth.

ORCL currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Key Takeaways PANW added 220 net new platformizations in fiscal Q4 2026, more than doubling its volume in two years.Platformized customers delivered net revenue retention above 120%, reflecting expanding product adoption.PANW secured $126 million and $72 million deals, expanding adoption across multiple security platforms. Palo Alto Networks (PANW - Free Report) is seeing strong momentum in its platformization strategy, which enables customers to standardize multiple security products on a unified architecture rather than relying on several separate tools. The company says this approach brings security data and policies together across control points, helping customers simplify operations and respond to threats in real time. PANW is using this strategy across Network Security, Cortex and Idira, while also expanding into areas such as SASE, AI security and observability.

The strategy is gaining traction with customers. In the fourth quarter of fiscal 2026, PANW added approximately 220 net new platformizations, more than twice the volume recorded when it began tracking the metric two years ago. The company also reported net revenue retention above 120% for its platformized customer cohort in the fourth quarter, indicating that customers are expanding their use of the platform.

Customer deals in the fourth quarter showed how Palo Alto Networks is using platformization to increase sales across products. A global telecom leader signed a $126 million agreement to expand its next-generation firewall footprint and replace legacy proxy providers with Prisma Access for SASE. A premier IT service provider signed a $72 million transaction covering Network Security, Cortex and Idira, with eight-figure investments in each. PANW also secured a $53 million deal with a leading global payments platform, which included a high-seven-figure commitment to Prisma AIRS as the customer expanded its enterprise AI initiatives.

The strategy is supporting growth across PANW's major platforms. Network and AI Security revenues grew 17% in fiscal 2026, while Cortex revenues rose 25% and Idira generated $1.26 billion in pro forma revenues, up 21%. PANW is targeting more than 4,000 platformizations by fiscal 2030 as part of its goal of reaching $20 billion in NGS ARR. The strong adoption of platformization and expansion across multiple security products provide a base for continued growth. As of now, PANW will need to maintain customer adoption and execute well across its expanding product portfolio to sustain this momentum.

How Competitors Fare Against PANWCompetitors like CrowdStrike (CRWD - Free Report) and SentinelOne (S - Free Report) are also gaining ground through platform expansion and AI innovation.

CrowdStrike ended its second quarter of fiscal 2027 with $5.84 billion in ARR, reflecting 25% year-over-year growth. The robust increase was fueled by the growing adoption of CrowdStrike’s Falcon Flex subscription model.

Though comparatively a small competitor, SentinelOne posted second-quarter fiscal 2027 year-over-year growth of 22% in its ARR. The growth was fueled by the rising adoption of SentinelOne’s AI-first Singularity platform and Purple AI.

PANW’s Price Performance, Valuation & EstimatesShares of Palo Alto Networks have jumped 115.1% in the year-to-date period compared with the Zacks Security industry’s appreciation of 104.7%.

PANW’s YTD Price Return Performance
Image Source: Zacks Investment Research

From a valuation standpoint, Palo Alto Networks trades at a forward price-to-sales ratio of 22.36X compared with the industry’s average of 20.17X. The Zacks Value Score of F suggests that PANW stock is overvalued.

PANW Forward 12-Month P/S Ratio
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for Palo Alto Networks’ fiscal 2027 and 2028 earnings implies year-over-year growth of 8.9% and 17.6%, respectively. The estimates for fiscal 2027 have been revised up by 7 cents over the past 30 days. The same for fiscal 2028 has been revised down by 2 cents over the past 30 days.

Image Source: Zacks Investment Research

Palo Alto Networks currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Jefferies said successful execution of Emitel’s growth strategy could deliver 60% valuation upside for the business and increase Cordiant Digital Infrastructure Ltd (LSE:CORD, FRA:86L)’s net asset value by 34%.

The broker reached the estimate after a site visit to Emitel in Kraków, describing Cordiant’s largest asset as a multi-pillar growth opportunity.

Emitel represented 56% of Cordiant’s net asset value at 31 March 2026, making its future performance particularly important to the investment company.

Jefferies reported that Emitel had already achieved a compound annual growth rate of 8.5% in EBITDAaL, which refers to earnings after lease costs, between 2022 and 2025.

Free cash flow grew at a 25.5% compound annual rate over the same period, supporting management’s plans for further expansion across several businesses.

The broadcasting operation aims to digitise its core offering, win a new multiplex known as MUX-5 and develop products including 5G broadcasting.

Emitel also plans to double its tower portfolio from 776 sites while increasing the average number of mobile network operator tenants from 1.8 times to more than 2 times.

Tower expansion could accelerate through Emitel’s existing build-to-suit pipeline with Orange and potential acquisitions from smaller operators or mobile network operators.

The company is also pursuing adjacent markets including data centres, drone infrastructure and security, airspace management, and smart-city projects.

Emitel recently entered Poland’s data centre market by acquiring DC Blonie, a 2MW Warsaw site with Kyndryl as an anchor tenant under a five-year contract.

Jefferies highlighted further upside from filling the remaining space at the site, brownfield development at other Emitel locations and potential acquisitions.

Emitel is targeting high single-digit to low double-digit annual revenue growth and low double-digit annual EBITDA growth through 2030.

Management expects EBITDAaL to exceed PLN700 million in 2030, with the strategy backed by PLN600 million of growth capital expenditure between 2026 and 2030.

Jefferies stated that operational cash flow should fund most of that investment, with debt facilities offering additional support as needed.

The broker rates Cordiant Digital Infrastructure 'buy,' with the shares at 123p against a 52-week range of 96p to 128p, while no price target was provided in the note.

 | Source: The Ensign Group, Inc.

SAN JUAN CAPISTRANO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it acquired the operations of four facilities in Washington (i) “Burien Nursing and Rehabilitation”, a 140-bed skilled nursing facility located in Burien, WA; (ii) “Issaquah Nursing and Rehabilitation”, a 140-bed skilled nursing facility located in Issaquah, WA; (iii) “Park Ridge Nursing and Rehabilitation”, a 115-bed skilled nursing located in Shoreline, WA; and (iv) “Park West Nursing and Rehabilitation”, a 137-bed skilled nursing facility located in Seattle, WA. Each of these facilities is operated by an Ensign affiliated operator and is subject to a long-term triple net lease.

“The addition of these facilities represents an exciting opportunity to strengthen our presence in the Pacific Northwest and further expand our operations in Washington,” said Barry Port, Ensign’s Chief Executive Officer. “These facilities serve vibrant communities throughout the Seattle area, and we have tremendous confidence in our local leadership teams and their ability to support strong clinical programs while maintaining a resident-centered approach to care.”

Steve Farnsworth, President of Pennant Healthcare LLC, Ensign’s Washington-based subsidiary, added “These facilities have long served as important healthcare resources in their communities, and we are excited to build upon that legacy. Our local teams look forward to working closely with these amazing caregivers as we continue enhancing care for the residents and families in these communities.”

In an additional transaction on the same day, Ensign announced that it acquired the operations of eight facilities in Florida comprised of 713 additional skilled nursing beds and 66 independent living units. Every facility is operated by an Ensign affiliated operator and is subject to a long-term triple net lease.

In a separate transaction on the same day, Ensign announced that it acquired the real estate and operations of “Englewood Heights Nursing and Rehabilitation”, a 118-bed skilled nursing facility located in Pensacola, Florida. The real estate was acquired by a subsidiary of Standard Bearer Healthcare REIT, Inc., Ensign’s captive real estate company, and the facility is operated by an Ensign-affiliated tenant.

In another transaction on the same day, Ensign announced that it acquired the operations of seven facilities in Colorado comprised of 760 additional skilled nursing beds and 47 independent living units. All seven facilities are operated by an Ensign affiliated operator and are subject to a long-term triple net lease.

Additionally, Ensign announced that through subsidiaries of Standard Bearer Healthcare REIT, Inc. it acquired the real estate assets to five facilities that it had previously been operating under third-party triple net leases. These facilities total 755 skilled nursing beds and are now subject to long-term leases with subsidiaries of Standard Bearer.

As of today, Ensign's growing portfolio consists of 418 healthcare operations, which includes 50 senior living operations, across 18 states. Ensign subsidiaries, including Standard Bearer, own 189 real estate assets. Mr. Port reaffirmed that Ensign is actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living and other healthcare related businesses throughout the United States.

About EnsignTM

The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 418 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.

Contact Information

The Ensign Group, Inc., (949) 487-9500, [email protected]

SOURCE: The Ensign Group, Inc.

The data center boom has been good for Marvell Technology (MRVL +1.47%). Revenue has accelerated over the past few years and rose 36% year over year in the most recent quarter. Now, Marvell's newest custom chip deals with the biggest cloud builders could extend its growth runway.

On its Aug. 27, 2026, earnings call, the company raised its fiscal 2028 revenue outlook to $18 billion, with custom silicon expected to more than double. Its custom business has more than 20 design wins across Amazon, Alphabet (GOOG -1.70%)(GOOGL -1.70%), Microsoft, and Meta Platforms, but a recent deal with Alphabet could be the most significant yet.

Image source: Getty Images.

Marvell is embedding itself deeper into the AI supply chain These four hyperscalers are expected to spend roughly $745 billion this year, according to The Motley Fool's research, driven by the need for data center capacity. Those dollars should flow to suppliers like Marvell, as cloud leaders deploy custom artificial intelligence (AI) chips to manage costs and power consumption.

In July, Marvell signed a major agreement with Alphabet's Google spanning accelerators, storage controllers, network interface controllers, and memory controllers. These custom silicon programs will tie into Google's TPU ecosystem. Overall, the Google deal amounts to $120 billion in cumulative total revenue over six years, assuming certain milestones are met.

Marvell expects fiscal 2027 revenue to reach $12 billion, up from $8 billion in fiscal 2026. CEO Matthew Murphy said on the company's Aug. 27, 2026, earnings call that the company's revenue should pick up in the second half of this year, with its custom silicon business expected to more than double year over year in fiscal 2028, before accelerating "significantly" in fiscal 2029.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

1.47

%) $

3.87

Current Price

$

268.08

Marvell CEO sees Google boosting custom revenue opportunity Since June 2025, Murphy has guided to more than $10 billion of custom silicon revenue by fiscal 2029. On the recent earnings call, he added that the Google agreement "greatly increases the revenue opportunity for us in custom with some of that potentially starting in '29." The company plans to update its long-term revenue target at its upcoming Investor Day.

Marvell's other products, including networking, controllers, and memory interfaces, should also see revenue growth as demand rises for Google's TPUs and custom chips from other hyperscalers. Research from Cathie Wood's team at Ark Invest expects spending on custom chips to grow faster than overall compute spending, which would be a tailwind for Marvell.

Selling the compute chip and the surrounding components can be lucrative and support strong earnings growth. While a more custom-chip mix could pressure margins, management expects its adjusted operating margin to increase. Marvell expects to exit the current year with an adjusted operating margin between 38% and 40%, reach the top end next year, and grow operating expenses more slowly than revenue.

Key risks, valuation, and the next catalyst Marvell has to execute in a fast-moving AI compute market. It also depends heavily on Taiwan Semiconductor Manufacturing and other suppliers in Asia. Any disruption, including economic pressure, geopolitical risks, or natural disasters, could delay revenue targets. Of course, Marvell is also dependent on a booming data center market, and any regulation or other event that slows the data center build-out could derail its momentum.

The stock is priced for perfection at a forward price-to-earnings ratio of 60. Still, if Marvell delivers on its long-term revenue targets, shares could have meaningful upside. Analysts project earnings growth of roughly 46% annually over the next several years.

A near-term catalyst is Marvell's upcoming Investor Day on Oct. 6, 2026. If management raises its long-term outlook for custom silicon revenue, the market may start valuing Marvell like a durable long-term growth story, potentially lifting the stock.

Home BancShares, Inc. (NASDAQ:HOMB) will release its third quarter earnings report after the closing bell on Wednesday, Oct. 14.

Analysts expect the Conway, Arkansas-based company to report quarterly earnings of 64 cents per share, up from 61 cents per share in the year-ago period. The consensus estimate for HOMB’s quarterly revenue is $294.21 million. It reported $280.59 million last year, according to Benzinga Pro.

On July 22, Home BancShares raised its quarterly dividend from 21 cents to 21 cents per share.

Shares of Home BancShares rose 1.4% to close at $28.56 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Cantor Fitzgerald analyst Dave Rochester maintained a Neutral rating and raised the price target from $30 to $31 on Aug. 19, 2026. This analyst has an accuracy rate of 59%. Citigroup analyst Benjamin Gerlinger maintained a Neutral rating and boosted the price target from $29 to $32 on July 21, 2026. This analyst has an accuracy rate of 51%. Piper Sandler analyst Stephen Scouten maintained an Overweight rating and increased the price target from $33 to $36 on July 17, 2026. This analyst has an accuracy rate of 74%. Stephens & Co. analyst Matt Olney maintained an Overweight rating and raised the price target from $32 to $35 on July 17, 2026. This analyst has an accuracy rate of 69%. Keefe, Bruyette & Woods analyst Christopher Mcgratty maintained a Market Perform rating and raised the price target from $30 to $32 on July 17, 2026. This analyst has an accuracy rate of 65%. Considering buying HOMB stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Amazon's (AMZN.O) cloud computing division said on Friday it would invest more than $1 billion over the next five ​years in US communities where it has data centers and ‌vowed to tackle their impacts on electricity and water usage.

Data centers, which provide the computing power to train and run AI models, have drawn opposition in ​communities nationwide over concerns about electricity demand, utility costs ​and other local impacts. The backlash poses a political challenge for ⁠Republicans heading into the US midterm elections on November 3.

Amazon ​said it had invested $276 billion in data centers between 2011 and 2025 ​and had large projects or expansions in the works in many states including Indiana, Louisiana, North Carolina, Virginia and Mississippi.

Amazon Web Services said the community investment ​plans announced on Friday would include spending on education, job training, ​energy affordability, water and energy preservation and other local priorities in parts of ‌the ⁠US where it has data centers.

The company in a lengthy statement sought to rebut criticism of data centers tied to environmental, energy and economic impacts and noted there were more than 100 data center moratoriums ​being considered across ​the country.

"There is ⁠urgency to this data center buildout because we aren’t the only country that sees the benefits ​of AI for the economy and national security, and ​the countries ⁠that lead in AI will shape it and get the most from it," AWS CEO Matt Garman said.

AWS also committed to being water ⁠positive ​across its data centers by 2030 by ​returning more water to communities than it uses and said it was 75% of ​the way toward its goal.

With more than one century of paying dividends under its belt, it's difficult to argue that ExxonMobil (XOM +0.66%) isn't dedicated to returning capital to investors.

But it's not only dividends that the company embraces to reward shareholders -- ExxonMobil is also committed to buying back shares in 2026. Let's take a look at how the company chose to return $9.4 billion in capital to shareholders in the second quarter of 2026.

Image source: Getty Images.

$9.4 billion returned to investors, and there's still more coming through the rest of the year One of the largest energy companies by market cap, according to recent research from The Motley Fool, ExxonMobil generated an impressive $26.1 billion in free cash flow in 2025. Of that, the company returned $17.2 billion in dividends to shareholders and bought back $20 billion in stock.

Premium Feature

Moneyball Superscore

70/100

Today's Change

(

0.66

%) $

1.07

Current Price

$

163.82

Little has changed so far in 2026 -- nor will it likely change if the company adheres to its guidance.

In Q1 2026, ExxonMobil returned $4.3 billion to shareholders in dividends and bought back $4.9 billion of stock. More recently, in Q2 2026, ExxonMobil returned $4.3 billion to investors through dividends and $5.1 billion through share buybacks.

Management has projected share repurchases totaling $20 billion for 2026, and it seems likely that the company will boost its dividend higher in the coming months when it reports third-quarter 2026 financial results.

Drilling down deeper into ExxonMobil's dedication to dividends While ExxonMobil's history of paying a dividend for more than a century is remarkable, it's only part of the story. The company also deserves recognition for its streak of hiking its payout higher for 43 consecutive years, a feat that distinguishes it from many of its dividend-paying peers.

Over the past four decades, management has proven adept at balancing the company's financial health with rewarding shareholders, a dynamic that will likely persist in the coming years. For income investors seeking an energy stock to help fuel their passive income streams, ExxonMobil stock is a worthy consideration.

Scott Levine has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Moderna stock NASDAQ:MRNA rose more than 2% in early premarket trading on Friday after Nasdaq said the biotech company will join the Nasdaq-100 next week, creating new demand from index-tracking funds.

The move follows a spectacular 2026 rally that has pushed Moderna more than 500% higher and transformed it from a post-pandemic recovery story into an oncology bet.

Yet Wall Street remains divided, as Citi downgraded Moderna to Sell this week, arguing that optimism around its personalised cancer vaccine has run too far ahead of the evidence.

Nasdaq-100 entry creates a new buyerNasdaq said Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on October 9.

The benchmark covers 100 large non-financial Nasdaq companies and is tracked by more than 200 investment products with over $800 billion globally.

That creates a mechanical distinction in Moderna’s rally.

Investors buying the stock because of its cancer pipeline are making a fundamental call on future revenue.

Funds that track or benchmark themselves against the Nasdaq-100, however, may need to add Moderna simply because the company is entering the index.

That helps explain Friday’s 2% premarket gain even though the underlying valuation debate has not changed overnight.

Index inclusion can support near-term demand, but it does not settle what the business is ultimately worth once rebalancing flows have passed.

Citi says the cancer story is already priced inCiti analyst Geoff Meacham downgraded Moderna to Sell from Neutral on September 30 while raising his price target to $80 from $60.

His central objection is valuation. “We struggle to justify the valuation through public-company comparisons or pipeline NPV,” Meacham wrote, according to Investing.com.

Citi said Moderna’s market value had moved close to Regeneron’s despite lower expected revenue and earnings.

Even assuming a 100% probability of success for Intisermin’s leading programmes, Citi supported only about $100 per share.

The bank also estimated that a share price around $200 would require roughly $26 billion in annual oncology sales, with approximately half going to Moderna and the remainder to partner Merck. That is nearly seven times Citi’s own forecast.

The contradiction is unusually sharp. Nasdaq-linked funds may soon have to buy Moderna regardless of valuation, while one of Wall Street’s most bearish analysts believes fundamental investors should be doing the opposite.

The bull case starts with the Phase 3 INTerpath-001 study.

Moderna and Merck said intismeran, combined with Keytruda, met its primary recurrence-free-survival endpoint and a key secondary endpoint in high-risk melanoma.

The result gave investors their clearest evidence yet that Moderna’s mRNA technology can create a meaningful commercial franchise beyond infectious-disease vaccines.

William Blair analyst Myles Minter upgraded Moderna to Outperform after the result, saying the company now has “a clear line of sight to revenue diversification from the COVID business”.

That is the strongest answer to Citi’s caution.

But the debate remains unsettled. Rothschild & Co Redburn analyst Simon Baker called the Phase 3 result “undoubtedly good” while arguing the share-price reaction was overexuberant because melanoma success does not prove Moderna can reproduce it across other tumour programmes.

That leaves two competing valuation frameworks. One treats intismeran as the beginning of a broad oncology platform, while the other sees one major clinical success being extrapolated too aggressively.

Nasdaq-100 inclusion now adds another layer to that argument. Passive funds may soon have little choice but to own Moderna, while fundamental investors remain split over how much cancer-vaccine success is already embedded in the price.

Micron Technology (MU +3.03%) is making cash much faster than it's spending it. The memory chipmaker's non-GAAP (adjusted) free cash flow was $62.3 billion for its fiscal year that ended Sept. 3 -- up from $3.7 billion in fiscal 2025. But the company spent just $650 million of it buying back its own shares.

Alongside its fiscal fourth-quarter results on Wednesday, Sept. 30, Micron said it plans to increase capital return starting Dec. 9. Over time, it intends to give all its excess cash back to shareholders.

Shares trade near $1,065 as I write, giving the company a market cap of about $1.2 trillion. How much of Micron could a buyback that large retire?

Image source: Micron.

A cash pile that keeps growingShowing how fast the cash is coming in, Micron's adjusted free cash flow (cash from operations minus net capital spending) was $33.2 billion in the fiscal fourth quarter, the final three months of the year. This compares to $18.3 billion in fiscal Q3 and just $803 million in the year-ago quarter. Revenue climbed 379% year over year to $54.2 billion, and net income surged almost 12-fold to $37.7 billion. In other words, the fourth quarter alone brought in over half of the year's free cash flow -- an impressive acceleration even for this memory boom.

Most of the cash still sits on the balance sheet. Micron finished the year with $73.5 billion in cash and investments against $5.2 billion in debt, leaving net cash of $68.3 billion.

Capital return, meanwhile, hardly registered. The $650 million buyback came to around 1% of the year's free cash flow.

And Micron spent more (about $1.1 billion) withholding shares from employees' stock awards to pay their taxes. Even with both, the diluted share count climbed around 1.4% year over year in the fourth quarter. And as of May 28, just $2.16 billion was left on the company's current repurchase authorization.

Why wait until December?The timing seems linked to Micron's federal CHIPS Act funding. The company's latest quarterly filing says its buyback authorization is subject to restrictions under its CHIPS Act direct funding agreements. And chief financial officer Mark Murphy pegged the bigger return to Dec. 9, 2026, the second anniversary of the signing of those agreements.

"Over time, we expect to return 100% of our excess cash to shareholders," Murphy said in his prepared remarks for the earnings call.

Later in the call, Murphy said Micron expects to be near its target cash level by the end of this fiscal quarter. He added that the excess would go back to shareholders mainly through buybacks, and that the company expects to seek a bigger authorization soon.

Notably, management hasn't said what that target cash level is.

The cash could retire around 5% of the stock a yearBecause management hasn't defined "excess cash," I'll use fiscal 2026's adjusted free cash flow as a stand-in, assuming Micron's cash already sits near the level it wants to hold.

At around $1,065 a share, $62.3 billion would buy back about 58 million shares in one year. That comes to around 5% of the roughly 1.13 billion shares Micron had outstanding in June.

Premium Feature

Moneyball Superscore

91/100

Today's Change

(

3.03

%) $

32.28

Current Price

$

1,097.39

I'd be more careful adding the $68.3 billion of net cash on top of that. Around $12.7 billion of Micron's cash is customer deposits linked to its long-term supply agreements, and the company expects to return that money to customers over time.

Free cash flow also faces a bigger spending plan. Micron expects around $25 billion of capital expenditures in just the first half of fiscal 2027, near the $27.4 billion of net capital spending in all of fiscal 2026. Still, Murphy said fiscal Q1 free cash flow should be much higher than the fourth quarter's $33.2 billion.

Of course, the price Micron pays matters, too. With the stock at about 14 times earnings, based on fiscal 2026 results, every dollar spent on shares buys about 7 cents of last year's profit. That price is arguably appealing if memory prices hold, but it might look expensive if fiscal 2026 ends up being a peak.

In the end, retiring roughly 5% of the share count a year would probably give earnings per share a steady boost. But that depends on memory prices staying near today's levels, and the higher spending doesn't begin until December. For now, I'd count the buyback as another point in Micron's favor and wait to see the share count drop.

Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer (TNBC).

“We believe this collaboration with Daiichi Sankyo and AstraZeneca reflects increasing conviction in ivonescimab’s potential as a foundational next-generation immunotherapy and advances our ambition for ivonescimab to become the global PD-1 / VEGF partner of choice for novel combinations,” said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. “Beginning with a Phase III study in first-line triple negative breast cancer, this collaboration represents an important expansion of Summit’s global development program into breast cancer and a path for additional solid tumor settings.”

Under the terms of the agreement, each company will contribute their respective therapies for the planned combination trials which will be sponsored by AstraZeneca or Daiichi Sankyo. AstraZeneca, Daiichi Sankyo, and Summit will each contribute to trial costs, and each company will retain development and commercial rights to their respective medicines.

“At Daiichi Sankyo, we are focused on maximizing the potential of our DXd antibody drug conjugate portfolio through innovative combinations and strategic collaborations that support the continued advancement of our pipeline,” said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. “We are encouraged by the opportunity to explore ivonescimab in combination with Datroway to potentially deliver clinically meaningful benefit to patients.”

“Central to our strategy to transform cancer outcomes is harnessing the power of immunotherapy and antibody drug conjugate combinations to drive deeper, more durable responses,” said Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca. “We believe the combination of Datroway and ivonescimab has the potential to make a meaningful difference in multiple tumor types including lung and breast cancers.”

Datroway is a specifically engineered TROP2-directed DXd ADC discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. Designed using the proprietary DXd ADC Technology of Daiichi Sankyo, Datroway is one of seven DXd ADCs in the oncology pipeline of Daiichi Sankyo.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was engineered by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 16 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, one of which is a multiregional study sponsored by a cooperative group, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC, commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3. In 2025, Summit began enrolling patients in HARMONi-7. Summit expanded its Phase III clinical development program into colorectal cancer (CRC) in the fourth quarter of 2025 by initiating enrollment in HARMONi-GI3. In 2026, Summit announced initiation of HARMONi-GU1, a Phase II/III study in urothelial carcinoma (bladder cancer) with global clinical trial site activations planned to begin by the fourth quarter of 2026.

HARMONi is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR TKI (e.g., osimertinib). Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization, which the FDA accepted for filing in January 2026; the goal Prescription Drug User Fee Act (PDUFA) date is November 14, 2026.

HARMONi-3 is a Phase III clinical trial evaluating ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous or non-squamous NSCLC, irrespective of PD-L1 expression. The clinical trial is evaluating the two histologies as individual, separately powered cohorts with independent statistical powering.

HARMONi-7 is a Phase III clinical trial evaluating ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.

HARMONi-GI3 is a Phase III clinical trial evaluating ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy in patients with first-line unresectable metastatic CRC.

HARMONi-GU1 is a Phase II/III clinical trial evaluating ivonescimab plus the antibody drug conjugate (ADC) enfortumab vedotin (EV) compared to pembrolizumab plus EV as first-line therapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

ILLUMINE is a Phase III study being conducted by GORTEC, a cooperative group dedicated to Head and Neck Oncology, in recurrent / metastatic head and neck squamous cell carcinoma (r/m HNSCC). ILLUMINE is a three-arm Phase III clinical trial designed to evaluate ivonescimab monotherapy, as well as ivonescimab in combination with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal antibody, compared to monotherapy pembrolizumab in patients with PD-L1 positive r/m HNSCC.

Five Phase III ivonescimab clinical trials have read out to date, all five with positive data. Four of these five studies are in NSCLC, and one is in biliary tract cancer (BTC). In addition to Summit’s positive HARMONi study, Akeso has had positive read-outs in three single-region (China), randomized Phase III clinical trials, HARMONi-A, HARMONi-2, and HARMONi-6, for ivonescimab in NSCLC, including a statistically significant overall survival benefit in all three studies from China. Akeso has also reported a statistically significant OS benefit in the single-region (China), randomized Phase III HARMONi-GI1 trial in advanced BTC.

HARMONi-A was a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR TKI.

HARMONi-2 is a Phase III clinical trial evaluating monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression.

HARMONi-6 is a Phase III clinical trial evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC, irrespective of PD-L1 expression.

HARMONi-GI1 is a Phase III clinical trial evaluating ivonescimab in combination with chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced BTC.

Akeso is actively conducting additional Phase III clinical studies in settings outside of NSCLC and biliary-tract cancer, including triple-negative breast cancer, head and neck squamous cell carcinoma, small cell lung cancer, colorectal cancer, and pancreatic cancer.

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company’s shares are listed on the Nasdaq Global Market (symbol "SMMT"). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Summit Forward-Looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the risk that the private placement does not close on the anticipated timeline or at all, including because required regulatory clearances are not obtained or other closing conditions are not satisfied, dilution to existing stockholders, and potential adverse effects on the market price of the Company's common stock, including from future sales by AstraZeneca, the Company's broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca’s ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company's reliance on AstraZeneca for the supply of AstraZeneca’s products and other contributions to the clinical trials, the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company's anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright © 2026, Summit Therapeutics Inc. All Rights Reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261001197318/en/

3 Micro-Caps Set for Major Moves: Balancing Risk and OpportunityComstock NYSEAMERICAN: LODE has begun continuous operations at its industrial-scale solar-panel recycling facility in Nevada, marking what Chief Executive Officer Corrado De Gasperis described as a significant step in the company’s shift toward renewable metals and commercialization of its technologies.

Speaking at the Lytham Partners Fall 2026 Investor Conference, De Gasperis said the facility is operating 24 hours a day, seven days a week. He characterized the operation as reaching technology readiness level 8, a stage generally associated with systems demonstrated at industrial scale.

Get Comstock alerts:

“We’re up and running. We’re running 24/7. We’re running at scale,” De Gasperis said, adding that the company does not see other companies currently operating a comparable process.

Solar recycling capacity and process The Nevada facility has annual capacity to process 3.3 million solar panels, according to De Gasperis. Its processing system includes four ovens, with each oven representing roughly 25% of total facility capacity. The company has also completed an adjacent storage facility for panels awaiting processing.

De Gasperis said the recycling process is designed to separate contaminants and produce clean aluminum, glass and mineral-rich tailings. The company has further worked to separate residual metals from recovered glass in an effort to meet specifications sought by glass-reprocessing customers.

According to De Gasperis, the process is intended to avoid generating hazardous waste while reducing liability for customers disposing of end-of-life solar panels. The facility includes environmental-control equipment, including a scrubber for potential particulates or opacity, he said.

The plant also uses two robotic arms to feed panels into the system. De Gasperis said the automation supports a targeted processing pace of one panel every seven seconds or less.

Annual capacity: 3.3 million solar panels Processing configuration: Four ovens at the Nevada facility Operations: Continuous, 24-hour and seven-day-per-week production Output materials: Clean aluminum, clean glass and mineral- or silver-rich tailings Comstock is also developing methods to extract higher-value materials from the tailings, including silver, copper, silicon metals and silica, De Gasperis said. In some cases, the tailings may contain rarer materials as well.

Expansion planning and market development De Gasperis said Comstock has designed a second recycling facility intended for the Mid-Atlantic and Midwest markets, including Ohio, Pennsylvania and Indiana. The planned facility would initially use one oven but would use the same process and could eventually expand to four ovens, he said.

The company has not yet committed capital to construct the second facility. De Gasperis said the approach is intended to support “intelligent capital deployment” while allowing for faster expansion as demand develops.

Comstock selected Nevada for its first facility in part because older solar-panel installations in California, Arizona and Nevada created a substantial nearby market, De Gasperis said. He also identified Ohio, North Carolina, Florida and Texas as markets where solar panels are reaching end of life.

While panels are currently being shipped from across the country to Nevada, De Gasperis said the company views that activity as evidence of limited recycling alternatives for customers. He said Comstock is willing to absorb temporarily higher shipping costs in some circumstances to develop national accounts, secure key customers and build market share.

The company plans to operate the Nevada plant at about 25% of its capacity for several months to demonstrate its stability and unit economics before expanding market activity through 2027 and 2028, De Gasperis said. Over time, he said, Comstock’s goal would be to establish recycling facilities in multiple locations, with five facilities viewed as an ideal footprint.

Silver Springs opportunity Beyond renewable metals, De Gasperis discussed Comstock’s interest in Sierra Springs Opportunity Fund Inc., a land platform in Silver Springs, Nevada. He said the region benefits from Nevada’s economic and tax environment, federal Opportunity Zone advantages, improved highway connectivity and interest from technology and data-center-related development.

De Gasperis cited Microsoft and Tract as companies breaking ground in the Silver Springs area, while noting that the region’s local and state governments have been supportive of development. He said Comstock also maintains investments in renewable fuels, though the company’s capital allocation and primary focus are centered on renewable metals.

About Comstock (NYSEAMERICAN:LODE)Comstock Inc is a technology and natural resources company focused on developing solutions for the energy transition and the circular economy. The company's activities include renewable fuels, solar technology and mineral processing, with an emphasis on converting underused or waste materials into products that can support lower-carbon energy systems.

Through its Comstock Fuels business, the company is developing technologies intended to convert woody biomass and other non-food feedstocks into renewable fuels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Comstock Right Now?Before you consider Comstock, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Comstock wasn't on the list.

While Comstock currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

New Development Center Boosts Testing and Evaluation Capabilities on Road to Electrification

, /PRNewswire/ -- The next chapter of Toyota's electrification transformation begins today with the opening of the Toyota Battery Center of North America (TBC) in Saline, Michigan. The new facility gives Toyota's Michigan-based battery teams increased capabilities to evaluate and develop technology across the full battery-development cycle, from sourcing raw materials to customer applications to recycling.  

Toyota Battery Center of North America Unveiled at Michigan R&D Campus "Toyota has long been at the forefront of battery development," said Keita Moritsu, Senior Vice President and Chief Technology Officer, Toyota Motor North America R&D. "This center is where that leadership expands to North America — and where we're building its next chapter." 

The 30,000-square-foot facility serves as a central hub for development and evaluation, in partnership with Toyota's North American manufacturing network, supporting the evaluation of batteries for Toyota Battery Manufacturing, North Carolina, as well as Toyota's vehicle manufacturing plants across North America. 

TBC also represents the latest milestone in Toyota's more than 50-year history with the state of Michigan. 

"Today is a big win for Michigan's leadership in advanced automotive manufacturing," said Michigan Governor Gretchen Whitmer. "We are proud to welcome this investment by Toyota that positions Michigan as the best place to build the future. This state-of-the-art facility will develop, test, and improve the batteries powering the next generation of vehicles. It joins factories and projects opening across our state that are creating good-paying, high-skilled jobs in every community. Let's keep working together to build the future of cars, chips, batteries, and so much more right here in Michigan."

TBC's evaluation and development capabilities support Toyota's multi-pathway strategy by enabling a range of sustainable mobility solutions for customers. On site, teams of engineers and technicians assess battery performance and develop new technologies for use in hybrid, plug-in hybrid, hydrogen, and fully electric vehicles. 

"For Toyota customers, this facility means Toyota engineers can detect and resolve field concerns faster and closer to the source," said Jordan Choby, Group Vice President of Powertrain. "It also means we can develop longer-lasting batteries designed to perform in the conditions American drivers face every day." 

Toyota will open the facility and research access with the University of Michigan Electric Vehicle Center, allowing other research partners to benefit from its cutting-edge testing and evaluation capabilities. As a founding member of the Electric Vehicle Center, this program is part of Toyota's commitment to developing the next generation of battery engineers and technicians in Michigan.

About TMNA R&D
For more than 50 years, Toyota's Research & Development groups in North America have participated in engineering projects for several of the best-selling Toyota vehicles on U.S. roads. Teams are now creating both next-generation vehicles and new and advanced mobility concepts that can better move people, goods and information. Centered in Ann Arbor, Michigan, Toyota's North American R&D groups are pursuing Toyota's mission to "Produce Happiness for All" by making life safer, easier and more enjoyable. 

MEDIA CONTACT
Dan Nied
[email protected] 

SOURCE Toyota Motor North America

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Celsius Holdings, Inc. ("Celsius" or the "Company") (NASDAQ: CELH) and certain officers.   The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 26-cv-62465, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Celsius securities between February 21, 2025 and June 3, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Celsius securities during the Class Period, you have until November 3, 2026, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Celsius develops, processes, manufactures, markets, sells, and distributes products including energy drinks.

On April 1, 2025, Celsius closed the acquisition of Alani Nutrition LLC ("Alani Nu"), a maker of highly caffeinated energy drinks (described in greater detail below), for a net purchase price of $1.65 billion, comprised of cash and stock.

At all relevant times, Defendants represented that their products, including specifically Alani Nu drinks, were safe and healthy. For example, as of the time this Complaint was filed, Alani Nu's website continues to represent that "we use ingredients you can feel good about without compromising taste."

However, in contrast to Defendants' representations, Alani Nu drinks present serious risks due to the amount of caffeine they contain. A single 12-ounce Alani Nu drink contains 200 milligrams of caffeine, more than other popular energy drinks and more than twice the 100-milligram daily limit of caffeine recommended for teenagers and children aged 12 to 17, according to leading bodies of pediatricians and adolescent psychiatrists. The Center for Disease Control has stated that consumption of energy drinks in this age range can lead to cardiovascular issues ranging from irregular heartbeat to heart failure.

Alani Nu drinks have previously been the subject of regulatory action. In August of 2023, the Canadian Food Inspection Agency warned Canadians "[d]o not consume, use, sell, serve, or distribute" Alani Nu energy drinks, stating that the drinks "are being recalled from the marketplace due to various non-compliances related to caffeine content and labelling requirements." Specifically, Alani Nu's caffeine content exceeded Canada's legal limit of 180 milligrams for a single-serving energy drink.

Despite the risks that Alani Nu drinks present to consumers under the age of 18, Defendants at all relevant times have marketed these drinks to such consumers despite asserting their purported commitment not to do so. Alani Nu drinks are packaged in dynamic, bright colors, and Alani Nu actively recruits college students to join the "Alani Ambassadors" program and market Alani Nu products using their profiles on social media platforms such as Instagram and TikTok. As of the filing of this Complaint, the Alani Nu website even concedes that Defendants work with individuals whose social media audiences are comprised up to 25% of individuals under the age of 18.

While the labels on Alani Nu energy drinks state the amount of caffeine one can contains and generally state that they are "not recommended for consumption by children", they contain no similar cautionary language with respect to teenagers.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants' products failed to adequately disclose the cardiac risks of consuming Alani Nu products; (ii) by marketing Alani Nu drinks to consumers under the age of 18, the Company was marketing its products to individuals who were particularly susceptible to known health risks posed by those products; (iii) the foregoing created a non-speculative risk that Alani Nu consumers would suffer potentially fatal adverse health events; (iv) the foregoing, once revealed, was likely to have a significant negative impact on the Company's business and reputation; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on April 9, 2026, when NBC News and local news outlet MyRGV (Rio Grande Valley) reported that the family of 17-year old Texas cheerleader Larissa Rodriguez had filed a wrongful death lawsuit in Hidalgo County District Court against Glazer's Beer and Beverage, LLC ("Glazer's") and Glazer's Beer and Beverage of Texas, LLC, two distributors of Alani Nu. The family alleged that Rodriguez died from an enlarged heart caused by drinking Alani Nu energy drinks and that the drinks "had inadequate warnings about the serious cardiac risks" of drinking Alani Nu. According to NBC News, Celsius stated in response, inter alia, "our policy is not to market or sample to anyone under 18".

On this news, Celsius's stock price fell $1.52 per share, or 4.18%, to close at $34.86 on April 10, 2026.

Then, on June 4, 2026, Texas Attorney General Ken Paxton ("Paxton") announced an investigation into Celsius over concerns that its high-caffeine energy drinks are being marketed to children and teens. Per Attorney General Paxton's announcement, the investigation will specifically examine whether Celsius and its Alani Nu subsidiary had violated the Texas Deceptive Trade Practices Act by misrepresenting the safety of their products.

On news of the investigation, Celsius's stock price fell $2.26 per share, or 7.53%, to close at $27.75 per share on June 4, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

BlackBerry Shifts Gears With Coretura DealMobileye Global NASDAQ: MBLY said its core advanced driver-assistance systems business has strengthened in 2026, while the company works to expand its higher-content hands-free driving offerings and develop a more vertically integrated robotaxi strategy.

Speaking with Evercore ISI Head of Global Auto and Mobility Chris McNally, Chief Communications Officer Dan Galves acknowledged that several anticipated SuperVision partnerships “didn't really materialize” in their first round. Still, he said the company sees reasons for optimism in its core ADAS business, emerging-market growth and planned launches with automakers including Porsche.

Get Mobileye Global alerts:

Core ADAS Volume Outlook Improves 3 Robotics Stocks Under $10: Value, Momentum, or Bet?Galves said Mobileye expects approximately 10% volume growth based on its July guidance, compared with an original expectation for 4% growth. He attributed the projected growth to roughly 3% from China exports, 3% from first-quarter safety-stock increases and 4% growth among its top 10 customers.

That customer growth compares with an estimated 5% decline in global production among those top 10 OEM customers, according to Galves. He said the company’s growth relative to customer production reflects strong performance despite a sluggish broader auto-production environment.

Forget Tesla: These 2 Earnings Reports Reveal Where the Auto Market Is HeadingChina-based automakers have increased exports as their domestic market remains weak, Galves said. Mobileye has stronger share on export vehicles, particularly with Chery and Geely, than it does on vehicles sold in China. He said exports are reaching markets including Russia, Brazil, Malaysia and Australia, rather than being concentrated in Western Europe.

According to Galves, low ADAS penetration in those markets is prompting legacy automakers to standardize more ADAS content. He cited S&P data showing about 1 million to 1.5 million units of emerging-market ADAS adoption growth this year and said Mobileye expects that figure could be revised higher.

Looking further ahead, Galves identified India as a significant potential growth market, citing Mobileye’s position with Mahindra and Tata as well as regulations expected in 2027. However, he said growth beyond roughly 40 million units will not be easy because of production declines among some major customers and already-high ADAS penetration in North America and Western Europe.

Hands-Free Systems Offer Higher Content Opportunity Mobileye sees highway hands-free Level 2+ systems as the largest near-term growth opportunity in ADAS. Galves distinguished those products from point-to-point systems, which can drive a vehicle to a destination across varied road types and conditions.

While point-to-point systems such as Tesla’s Full Self-Driving receive considerable attention, Galves said highway hands-free systems are expected to account for more volume over the next several years. He cited an estimated 18% compound annual growth rate for the segment over the next two to three years.

The company has secured two major new “Surround ADAS” programs with Volkswagen and a large U.S. OEM, Galves said, while BMW elected to continue working with Qualcomm. Surround ADAS includes multiple cameras, radars, an EyeQ6 High processor and Mobileye-provided software for capabilities including parking and driver monitoring.

Galves said the systems can lower costs for automakers. In one program, he said Mobileye expects to reduce the OEM’s current cost to approximately $400 from about $1,200. The company expects Surround ADAS to generate two to three times the average selling price of a base system while maintaining the same gross-margin profile.

Mobileye also discussed its Cloud-Enhanced ADAS offering, which Stellantis selected to add REM road intelligence to an existing EyeQ6 Lite program. Galves said the upgrade can increase average selling price to about $90 from $50, while gross profit per unit is similar to the more comprehensive Surround ADAS system.

Porsche Launch Seen as SuperVision Proof Point Galves said Mobileye’s SuperVision system with Porsche is scheduled to launch next year and could become an important proof point for its point-to-point capabilities. He said the Porsche program continues to indicate annual volume of roughly 300,000 to 350,000 units after several years, rather than in the initial 2027 launch year.

He said the launch could provide evidence that Mobileye can execute a next-generation system that competes with Tesla’s FSD. The company has also received calls concerning possible fallback programs, Galves said, as automakers pursue multi-supplier approaches and seek to retain their own intellectual property in point-to-point autonomy programs.

For its Chauffeur program with Audi, Galves said development is making good progress and remains on track for a planned second-quarter 2028 launch, though “a lot of work” remains.

Robotaxi Efforts Expand Beyond OEM Partnerships Mobileye said its existing robotaxi partnerships are advancing. Closed-user-group testing with Volkswagen ID. Buzz vehicles has begun in Orlando and has been underway for months in Hamburg, both with safety drivers. Los Angeles testing is occurring in Santa Monica and West Hollywood, while Oslo and Berlin are also target cities.

Galves said Mobileye’s partner HOLON, owned by BENTELER Group, has been selected as the production autonomous-vehicle partner for Deutsche Bahn’s KIRA initiative. The program is intended to integrate autonomous vehicles into public transportation in multiple German regions.

Mobileye is also pursuing its own vertically integrated robotaxi platform. Galves said the company intends to have vehicles delivered from automakers without self-driving equipment to an upfit facility, after which Mobileye would own the completed vehicle. That structure would allow the company to sell or lease vehicles to operators, deploy them in its own service, or use them in third-party services.

The company does not intend to necessarily operate a fully vertically integrated service in direct competition with Waymo, Galves said. Instead, it aims to establish a complete service and demonstrate driverless operation to improve its negotiating position with potential fleet-scale partners.

Galves said Mobileye expects to have AV-ready vehicles by the end of the year or early 2027 and believes an OEM could produce a purpose-designed variation of an existing vehicle platform in the thousands annually. He said the company believes it can bring the bill of materials cost for its self-driving system below $10,000, excluding the cost of the vehicle itself.

About Mobileye Global (NASDAQ:MBLY)Mobileye Global Inc is a technology company focused on advanced driver-assistance systems (ADAS) and autonomous driving. Its technologies are designed to help improve road safety and support automated driving through computer vision, artificial intelligence, sensor fusion and mapping.

The company develops and supplies products for automakers and mobility providers, including EyeQ system-on-chips, camera-based driver-assistance features, SuperVision hands-free driving technology, and autonomous driving platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Mobileye Global Right Now?Before you consider Mobileye Global, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mobileye Global wasn't on the list.

While Mobileye Global currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

AMSTERDAM--(BUSINESS WIRE)--Nebius (Nasdaq: NBIS), the AI cloud company, today announced it has acquired Inferize, an inference optimization company whose technology shortens the time needed to launch and scale large AI models, making inference workloads elastic.

Inferize's technology and team have joined Nebius Token Factory, Nebius's managed inference platform for production AI.

Cold starts – the time models need to load before serving a single request – impose additional time and costs on teams running AI models in production at scale. This leaves assigned GPUs idle at launch time, when demand spikes and new instances spin up, and when weights are updated mid-run for example during reinforcement learning – and forces platforms to hold spare capacity just to hit their service-level targets.

Inferize's technology cuts this “idle GPU tax”, enabling capacity to scale much more closely with actual usage and driving higher capacity utilization and better token economics.

Danila Shtan, Chief Technology Officer of Nebius, said:
“Running inference well takes more than fast GPUs and optimized models. The whole system needs to respond when demand changes, including how quickly additional capacity is ready to serve customers. Inferize brings technology that accelerates that process and a team with deep expertise in GPU systems. We’re bringing both into Token Factory to make it more responsive to customer demand and get more useful work out of our infrastructure. The team’s contribution will extend well beyond this first integration.”

Inferize adds another layer to how Nebius runs production inference. Eigen AI brought optimization at the model, kernel and system levels into Nebius Token Factory, while Clarifai's core team and licensed technology added system-level inference and compute orchestration.

Guy Bortnikov, co-founder and CEO of Inferize, said:
"Keeping spare GPUs running is the price of being ready for demand. Removing that cost is what we built Inferize to do, and Nebius is where it can go straight into the platform. Our team will work across the stack with one objective: serving more customer demand from every GPU."

Founded in January 2026, the Inferize team had a working prototype within three months. Inferize’s engineers will work across Nebius Token Factory, starting with the integration of their technology.

The terms of the transaction were not disclosed.

About Nebius

Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide.

Nebius is listed on Nasdaq (Nasdaq: NBIS) and headquartered in Amsterdam.

For more information please visit nebius.com.

Media kit nebius.com/media-kit.

Disclaimer

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our future financial and business performance, strategy, expected growth, planned investments and capital expenditures, capacity expansion plans, anticipated future financing transactions and expected financial results, are forward-looking statements. The words "anticipate," "believe," "continue," "estimate," "expect," "guide," "intend," "likely," "may," "will" and similar expressions and their negatives are intended to identify forward-looking statements.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. Actual results may differ materially from the results predicted or implied by such statements, and our reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted or implied by such statements include, among others: market, macroeconomic and geopolitical conditions; our ability to build, operate and manage our businesses to the desired scale; competitive pressures; technological developments; our ability to secure and retain clients; our ability to secure additional capital to enable the growth of the business; unpredictable sales cycles; and potential pricing pressures; as well as those risks and uncertainties related to our continuing businesses included under the captions "Risk Factors" and "Operating and Financial Review and Prospects" in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 30, 2026, which is available on our investor relations website at https://nebius.com/investor-hub and on the SEC website at www.sec.gov.

All information in this press release is as of the date hereof (unless stated otherwise). Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Sigma Lithium Corp (TSX-V:SGML, NASDAQ:SGML, ASX:SAU) said on Thursday it still expects to deliver 330,000 tonnes of lithium oxide concentrate in fiscal 2027, even as it temporarily suspended mining and industrial production in Brazil. 

The company halted operations on September 30 after a 15-day delay by the Federal Court of Appeals in reviewing its emergency motion for suspensive relief. It will postpone by three months its 12-month guidance of 240,000 tonnes. 

Sigma will keep its commercial and recycling operations running, including the recycling of 100% of its dry stacked tailings and sales of high-purity lithium fines. The company expects those activities to generate cash flow and self-fund it during the suspension. 

The case stems from a lawsuit filed by the NGO Ngolo seeking to suspend the company's environmental licences. Sigma said its Grota do Cirilo complex sits outside the Quilombo and the legal distance of environmental impact set by Brazilian law. It said the community's houses are about 11 km from the Barreiro Pit and 8 to 9 km from the Xuxa Pits. 

Sigma said its licences were issued between May 2019 and April 2023, before the community's RTID notices were published in November 2023. It described the licences as vested rights protected under Brazilian law. 

Should the appeals court rule against it, Sigma said it will pursue a further appeal in the superior federal courts. The company noted that Brazil's general election runoff concludes on October 25 and said a decision could be delayed. 

Sigma said it has helped create 19,000 direct and indirect jobs, benefiting about 80,000 people across 12 municipalities in the Vale do Jequitinhonha. Its programs include microcredit for more than 2,000 women entrepreneurs, 1,400 rainwater reservoirs for small farmers, drinking water access for its neighbouring community, and school projects serving about 776 children. 

In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo

Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare systems

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. Obesity is strongly associated with an increased risk of developing both cardiovascular disease and type 2 diabetes.1 Through its proven benefit in weight loss and its ability to improve certain cardiovascular risk factors like blood sugar, blood pressure and cholesterol, Foundayo may be a meaningful treatment option for the more than 100 million U.S. adults living with obesity.2 The findings of these analyses were published in Diabetes, Obesity and Metabolism.

"For many people living with obesity or overweight, the concern isn't just what the scale says today, it's whether their future could include type 2 diabetes or heart disease," said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. "These additional analyses of ATTAIN-1 show that Foundayo was associated with a lower predicted long-term risk of both conditions, in addition to meaningful weight loss. We've also seen evidence that treating obesity and reducing the risk of its downstream consequences, like cardiovascular disease and type 2 diabetes, can meaningfully lower healthcare costs.3,4,5 That gives us real optimism about what long-term Foundayo use could mean, both for patients and for the broader healthcare system."

In these analyses, modeling showed that Foundayo was associated with clinically meaningful improvements in predicted 10-year risk of type 2 diabetes and cardiovascular disease across all three doses.6 At 72 weeks, participants taking Foundayo 5.5 mg, 9 mg and 17.2 mg showed an estimated 45.0%, 50.0% and 57.0% reduction, respectively, in predicted type 2 diabetes risk versus placebo.7,8 Participants taking Foundayo 17.2 mg also showed an estimated 18.0% reduction in predicted cardiovascular disease risk versus placebo.

ATTAIN-1 Post-Hoc Analyses: Change in Predicted 10-Year Cardiometabolic Risk at 72 Weeks

Foundayo
5.5 mg

Foundayo
9 mg

Foundayo
17.2 mg

Placebo

Type 2 diabetes riski

Predicted 10-year type 2
diabetes risk at baseline

16.4 %

16.0 %

17.1 %

17.3 %

Change in predicted 10-year
type 2 diabetes risk at 72
weeks

-8.0 %

-8.8 %

-9.8 %

-1.7 %

Estimated type 2 diabetes risk
reduction vs. placeboii

45%

(HR = 0.55)

(95% CI 0.52, 0.60)

50%

(HR = 0.50)

(95% CI 0.47, 0.54)

57%

(HR = 0.43)

(95% CI 0.40, 0.47)

–

Cardiovascular disease riskiii

Predicted 10-year
cardiovascular disease risk at
baseline

8.5 %

8.5 %

8.7 %

8.9 %

Change in predicted 10-year
cardiovascular disease risk at
72 weeks

-0.6 %

-0.7 %

-1.0 %

0.6 %

Estimated cardiovascular
disease risk reduction vs.
placeboii

13%

(HR = 0.87)

(95% CI 0.83, 0.90)

15%

(HR = 0.85)

(95% CI 0.82, 0.89)

18%

(HR = 0.82)

(95% CI 0.79, 0.86)

–

iType 2 diabetes risk was estimated using the Cardiometabolic Disease Staging (CMDS) risk engine.

iiEstimated risk reduction versus placebo is approximated based on the model-based hazard ratio (HR); placebo was the reference group. 

iiiCardiovascular disease risk was estimated using the BMI-based Framingham risk engine. 

About Foundayo
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and the ATTAIN clinical trial program  
ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg and 17.2 mg as a monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial is the first Phase 3 study of this patient population in which treatment was evaluated as an adjunct to exercise and a balanced, healthy diet rather than a reduced-calorie diet. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan in a 3:3:3:4 ratio to receive either 5.5 mg, 9 mg or 17.2 mg Foundayo or placebo. The primary objective of the study was to demonstrate that Foundayo (5.5 mg, 9 mg or 17.2 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body weight.

All participants in the Foundayo treatment arms started the study at a dose of Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5.5 mg (via steps at 0.8 mg and 2.5 mg), 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). The trial was conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets.

The ATTAIN Phase 3 global clinical development program for orforglipron enrolled more than 4,500 people with obesity or overweight across two global registration trials (ATTAIN-1 & ATTAIN-2).

Endnotes and References

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102-S138. Centers for Disease Control and Prevention. Adult Obesity Facts. https://www.cdc.gov/obesity/adult-obesity-facts/index.html. Bjornson AM, Szabo SM, Donato BMK, Gardner M, Kuti E. Costs of obesity, obesity-related complications, and weight loss in the United States: A systematic literature review. J Manag Care Spec Pharm. 2025;31(9):851-861. Xue J, Anderson J, Huang A, Gou R, Sun H, Zhao J, Allende C, Hua H, Hohlbauch A, Chinthammit C. Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee-For-Service Beneficiaries. Diabetes Obes Metab. 2026. Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34(12):107730. D'Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. Guo F, Garvey WT. Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes. The Journal of Clinical Endocrinology & Metabolism. 2015;100(10):3871-7. Wilkinson L, Yi N, Mehta T, Judd S, Garvey WT. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: a nationwide cohort and modeling study. PLoS medicine. 2020;17(8):e1003232. U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:
❑  Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑  Do you have a history of diabetic retinopathy?
❑  Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑  Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑  Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑  Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo™ is a trademark of Eli Lilly and Company.

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed.  You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell yourhealthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.  If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly   
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 

Cautionary Statement Regarding Forward-Looking Statements  
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo (orforglipron) as a potential treatment for adults with obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Foundayo will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.  

SOURCE Eli Lilly and Company